These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25889595)

  • 1. The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes.
    Lapice E; Monticelli A; Cocozza S; Pinelli M; Cocozza S; Bruzzese D; Riccardi G; Vaccaro O
    J Transl Med; 2015 Mar; 13():85. PubMed ID: 25889595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between Pro12Ala polymorphism and albuminuria in type 2 diabetic nephropathy.
    Chen YN; Wang PW; Tung SC; Kuo MC; Weng SW; Chou CK; Chang CM; Tsa CJ; Taso CF; Shen FC; Chen JF
    J Diabetes Investig; 2020 Jul; 11(4):923-929. PubMed ID: 31912623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator activated receptor γ2 gene Pro12Ala gene polymorphism in type 2 diabetes and its relationship with diabetic nephropathy.
    Azab MM; Abdel-Azeez HA; Zanaty MF; El Alawi SM
    Clin Lab; 2014; 60(5):743-9. PubMed ID: 24839816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT.
    De Cosmo S; Motterlini N; Prudente S; Pellegrini F; Trevisan R; Bossi A; Remuzzi G; Trischitta V; Ruggenenti P;
    Diabetes; 2009 Dec; 58(12):2920-9. PubMed ID: 19720797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes.
    Caramori ML; Canani LH; Costa LA; Gross JL
    Diabetes; 2003 Dec; 52(12):3010-3. PubMed ID: 14633865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy.
    Jorsal A; Tarnow L; Lajer M; Ek J; Hansen T; Pedersen O; Parving HH
    Mol Genet Metab; 2008 Jul; 94(3):347-51. PubMed ID: 18467141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes.
    Stefanski A; Majkowska L; Ciechanowicz A; Frankow M; Safranow K; Parczewski M; Pilarska K
    Arch Med Res; 2006 Aug; 37(6):736-43. PubMed ID: 16824933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of peroxisome proliferator-activated receptor γ Pro12Ala gene polymorphism with type 2 diabetic nephropathy risk in Caucasian population.
    Zhou TB; Guo XF; Yin SS
    J Recept Signal Transduct Res; 2014 Jun; 34(3):180-4. PubMed ID: 24329532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study.
    Herrmann SM; Ringel J; Wang JG; Staessen JA; Brand E;
    Diabetes; 2002 Aug; 51(8):2653-7. PubMed ID: 12145184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients.
    Wirta OR; Pasternack AI; Mustonen JT; Koivula TA; Harmoinen A
    Nephrol Dial Transplant; 1996 Mar; 11(3):449-56. PubMed ID: 8671814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects.
    Wang L; Teng Z; Cai S; Wang D; Zhao X; Yu K
    Diagn Pathol; 2013 Jul; 8():118. PubMed ID: 23856170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro12Ala polymorphism of the PPARgamma2 locus modulates the relationship between energy intake and body weight in type 2 diabetic patients.
    Vaccaro O; Lapice E; Monticelli A; Giacchetti M; Castaldo I; Galasso R; Pinelli M; Donnarumma G; Rivellese AA; Cocozza S; Riccardi G
    Diabetes Care; 2007 May; 30(5):1156-61. PubMed ID: 17259473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2.
    Gouni-Berthold I; Giannakidou E; Müller-Wieland D; Faust M; Kotzka J; Berthold HK; Krone W
    J Hypertens; 2005 Feb; 23(2):301-8. PubMed ID: 15662218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D2 Thr92Ala and PPARγ2 Pro12Ala polymorphisms interact in the modulation of insulin resistance in type 2 diabetic patients.
    Estivalet AA; Leiria LB; Dora JM; Rheinheimer J; Bouças AP; Maia AL; Crispim D
    Obesity (Silver Spring); 2011 Apr; 19(4):825-32. PubMed ID: 20930717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism of Pro12Ala in the peroxisome proliferator-activated receptor gamma2 gene in Iranian diabetic and obese subjects.
    Mirzaei H; Akrami SM; Golmohammadi T; Doosti M; Heshmat R; Nakhjavani M; Amiri P
    Metab Syndr Relat Disord; 2009 Oct; 7(5):453-8. PubMed ID: 19558269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies.
    Zhang H; Zhu S; Chen J; Tang Y; Hu H; Mohan V; Venkatesan R; Wang J; Chen H
    Diabetes Care; 2012 Jun; 35(6):1388-93. PubMed ID: 22619290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum uric acid and progression of diabetic nephropathy in type 1 diabetes.
    Pilemann-Lyberg S; Lindhardt M; Persson F; Andersen S; Rossing P
    J Diabetes Complications; 2018 May; 32(5):470-473. PubMed ID: 29534864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Pro12Ala polymorphism in peroxisome proliferator-activated receptor-γ2 gene on metabolic syndrome risk: a meta-analysis.
    Zhang R; Wang J; Yang R; Sun J; Chen R; Luo H; Liu D; Cai D
    Gene; 2014 Feb; 535(1):79-87. PubMed ID: 24012868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene and diabetic retinopathy in Caucasians and Asians.
    Ma J; Li Y; Zhou F; Xu X; Guo G; Qu Y
    Mol Vis; 2012; 18():2352-60. PubMed ID: 22993484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Pro12Ala polymorphism of PPARγ2 modulates beta cell function and failure to oral glucose-lowering drugs in patients with type 2 diabetes.
    Masulli M; Della Pepa G; Cocozza S; Capasso M; Pignataro P; Vitale M; Gastaldelli A; Russo M; Dolce P; Riccardi G; Rivellese AA; Vaccaro O
    Diabetes Metab Res Rev; 2021 Mar; 37(3):e3392. PubMed ID: 32783395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.